Goldman Sachs Group Inc vs uniQure N.V. Ordinary Shares — how do they compare? Goldman Sachs Group Inc trades at $882.23 (market cap $259.70B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Goldman Sachs Group Inc is far larger — about 175.5× uniQure N.V. Ordinary Shares's market cap, and Goldman Sachs Group Inc pays a 2.24% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 100 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GS | QURE | |
|---|---|---|
Market Cap | $259.70B | $1.48B |
Volume | 4,939,526 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $1.15K | $70.59 |
52-Week Low | $744.60 | $9.03 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $263.03B | $728.62M |
Dividend Yield | 2.24% | — |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $891.91, down 0.23% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q3 2026) and improving profitability (net margin 31.68%, ROE 18.33%). Revenue growth accelerated to $58.28B in 2025 with guidance targeting $70B. Recent news highlights AI expansion and wealth management growth, though Q3 FICC business may soften.
GS presents a compelling value opportunity with attractive valuation (P/E 13.77) and 40% analyst buy ratings. Upside to $1,160 consensus target offers ~30% potential, supported by dividend growth and operational efficiency. Risks include market volatility, competitive pressures, and execution on AI/wealth management expansion. The balance sheet remains robust with $122B equity despite negative operating cash flows.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →